Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia. The company said it doesn’t intend ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

NUPLAZID (pimavanserin), Acadia’s treatment for Parkinson’s disease psychosis, delivered $168.5 million in Q2 2025 sales, representing a 7% increase year-over-year.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along with a high estimate of $38.00 and a low estimate of $22.00. Observing a ...

Contemporary research has brought psychosis out of the dark, transforming our relationship to it from one of fear and rejection to one of hope and recovery.

Contemporary research has brought psychosis out of the dark, transforming our relationship to it from one of fear and rejection to one of hope and recovery.

Nuplazid (pimavanserin) is already FDA-approved to treat psychosis caused by Parkinson's disease, but Acadia's hope to expanding that use to the Alzheimer's population were shot down by a complete ...